CN101185629A - Decitabine sustained-release preparation for treating solid tumor - Google Patents
Decitabine sustained-release preparation for treating solid tumor Download PDFInfo
- Publication number
- CN101185629A CN101185629A CNA2007102030552A CN200710203055A CN101185629A CN 101185629 A CN101185629 A CN 101185629A CN A2007102030552 A CNA2007102030552 A CN A2007102030552A CN 200710203055 A CN200710203055 A CN 200710203055A CN 101185629 A CN101185629 A CN 101185629A
- Authority
- CN
- China
- Prior art keywords
- decitabine
- acid
- lactide
- poly
- sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 title claims abstract description 248
- 229960003603 decitabine Drugs 0.000 title claims abstract description 248
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 129
- 239000003405 delayed action preparation Substances 0.000 title claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 120
- 239000007943 implant Substances 0.000 claims abstract description 116
- 238000013268 sustained release Methods 0.000 claims abstract description 76
- 239000012730 sustained-release form Substances 0.000 claims abstract description 76
- 229960004275 glycolic acid Drugs 0.000 claims abstract description 44
- 229920001577 copolymer Polymers 0.000 claims abstract description 42
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229950004403 polifeprosan Drugs 0.000 claims abstract description 24
- 230000001093 anti-cancer Effects 0.000 claims abstract description 23
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 7
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims abstract description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract description 6
- 201000005619 esophageal carcinoma Diseases 0.000 claims abstract description 6
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 5
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 5
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 5
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 5
- 238000002347 injection Methods 0.000 claims description 60
- 239000007924 injection Substances 0.000 claims description 60
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 50
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 46
- 229930195725 Mannitol Natural products 0.000 claims description 45
- 239000000594 mannitol Substances 0.000 claims description 45
- 235000010355 mannitol Nutrition 0.000 claims description 45
- 239000004626 polylactic acid Substances 0.000 claims description 39
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 34
- 239000002253 acid Substances 0.000 claims description 27
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 claims description 10
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 10
- OFJWFSNDPCAWDK-UHFFFAOYSA-N 2-phenylbutyric acid Chemical compound CCC(C(O)=O)C1=CC=CC=C1 OFJWFSNDPCAWDK-UHFFFAOYSA-N 0.000 claims description 9
- 229920000305 Nylon 6,10 Polymers 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 201000001514 prostate carcinoma Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000008275 breast carcinoma Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 4
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims description 4
- 201000010174 renal carcinoma Diseases 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 208000033781 Thyroid carcinoma Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000008261 skin carcinoma Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 3
- 201000000274 Carcinosarcoma Diseases 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 210000001508 eye Anatomy 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000004907 gland Anatomy 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 40
- 229940079593 drug Drugs 0.000 abstract description 32
- 238000000034 method Methods 0.000 abstract description 31
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 201000007270 liver cancer Diseases 0.000 abstract description 3
- 208000014018 liver neoplasm Diseases 0.000 abstract description 3
- 201000005202 lung cancer Diseases 0.000 abstract description 3
- 208000020816 lung neoplasm Diseases 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000001959 radiotherapy Methods 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 201000001531 bladder carcinoma Diseases 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 230000006837 decompression Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 239000003960 organic solvent Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000012856 packing Methods 0.000 description 8
- 230000001954 sterilising effect Effects 0.000 description 8
- 230000005760 tumorsuppression Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 239000002131 composite material Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 238000005303 weighing Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- -1 chrondroitin Substances 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 201000001475 prostate lymphoma Diseases 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A decitabine sustained release implant for treating solid tumors is characterized in that the sustained release implant includes effective dose of anticancer decitabine, sustained release excipients and a certain quantity of sustained release moderator. Solid tumors include lung cancer, esophageal carcinoma, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic carcinoma, bladder carcinoma and colorectal cancer. Sustained release excipients are mainly one or combination of copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly(L-lactide-co-ethyl phosphate); in the process of decompression, decitabine can be slowly released to local tumor, thus maintaining effective drug concentration of local tumor as well as significantly reducing overall toxic reaction. Being placed in local tumor, the sustained release implant not only reduces overall toxic reaction of decitabine, but also selectively improves drug concentration in local tumor, thus enhancing the therapeutic effects of non-operative therapy such as chemotherapy drugs and radiotherapy.
Description
(1) technical field
The present invention relates to a kind of decitabine sustained-release preparation for the treatment of entity tumor,, belong to technical field of pharmaceuticals for sustained-release implant or slow releasing injection.
(2) background technology
Cancer morbidity rises year by year and is rejuvenation trend, has data to show that in less than the time in 20 years, China's cancer morbidity has risen 69%, and mortality rate has increased by 29.4%.According to World Health Organization's recent statistics, will increase by 50 percent to the year two thousand twenty whole world cancer morbidity, number of the infected increases to 15,000,000.Estimate that the year two thousand twenty China will have 4,000,000 people to die from cancer therefore every year, inquire into the focus that a kind of effective treatment method for cancer or medicine have become present research.
(3) summary of the invention
Based on above examination to prior art, the present invention has carried out studying extensively and profoundly to decitabine (Decitabine), sensitivity to its mechanism of action, route of administration and different entities tumor compares, the result shows, this chemical compound is used for that separately entity tumors such as the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, bladder cancer, carcinoma of testis, colon cancer and rectal cancer are had comparatively significantly action effect, but general toxicity is more obvious.Discover that further the decitabine local sustained release has good therapeutical effect to the outer entity tumor of other craniums such as thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma and carcinoma of prostate.Obtained the anti-tumor effect that conventional method is difficult to realize.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.
The present invention is directed to the deficiencies in the prior art, a kind of sustained-release implant is provided, be used for the treatment of entity tumor, not only effect is obvious, and its general toxicity obviously alleviates.
Outside first, specific slow-release auxiliary material has tangible influence to the release behavior of this medicine.
The present invention treats the sustained-release implant of entity tumor, it is characterized in that this sustained-release implant contains the decitabine of effective anticancer, slow-release auxiliary material and a certain amount of slow release regulator, and wherein the weight ratio of each constituent is:
(1) decitabine 0.1%-45%
(2) slow-release auxiliary material 55%-99%
(3) slow release regulator 0-15%
The percentage by weight of decitabine of the present invention in sustained-release implant serves as preferred with 0.1 to 45%, with 5%-30% for most preferably.Decitabine can be various salt, serves as preferred with phosphate and phosphate (decitabine).
Decanedioic acid (SA) copolymer), a kind of or its combination among poly-(L-lactide-co-etherophosphoric acid) (p (LAEG-EOP)), poly-(L-lactide-co-phosphoric acid propyl ester) (p (DAPG-EOP)) slow-release auxiliary material of the present invention mainly is selected from the copolymer (PLGA), polifeprosan of polylactic acid (PLA), glycolic and hydroxyacetic acid (to carboxy phenyl propane (p-CPP):.
Wherein the molecular weight peak value of the copolymer of glycolic and hydroxyacetic acid (PLGA) is 8000-15000,15000-35000,35000-45000 or 45000-80000; Serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.The percentage by weight of glycolic and hydroxyacetic acid is 90: 10,80: 20, and 75: 25,70: 30,60: 40,50: 50 or 40: 60; Wherein with 80: 20,75: 25,70: 30,60: 40, be preferred at 50: 50, with 60: 40 and 50: 50 for most preferably.
The molecular weight peak value of polylactic acid (PLA) is 8000-15000,10000-20000,20000-35000 or 30000-50000; Serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.
The molecular weight peak value of poly-(L-lactide-co-etherophosphoric acid) is 5000-15000,10000-20000,20000-35000 or 30000-50000, serve as preferred wherein with 5000-15000,15000-35000,35000-45000, with 15000-35000 for most preferably.
Polifeprosan (to carboxy phenyl propane (p-CPP): the percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) decanedioic acid (SA) copolymer) is 10: 90,20: 80, and 30: 70,40: 60,50: 50 or 60: 40; Wherein with 80: 20,70: 30,60: 40, be preferred at 50: 50, with 60: 40 and 50: 50 for most preferably.
The slow release regulator is selected from a kind of or its combination in xylitol, oligosaccharide, chitin, potassium salt, sodium salt, mannitol, sorbitol, hyaluronic acid, collagen protein, chrondroitin, gelatin and the albumin.
Slow-release auxiliary material also can be liquid, as, but be not limited to Oleum sesami, suspension, distilled water, physiology towards liquid and semisolid, as (but being not limited to) fruit jelly, paste, ointment etc., above-mentioned slow-release auxiliary material is applicable to the compositions that contains or do not contain additive
The consumption of slow releasing agent depends on several factors, as, but be not limited to gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.But its principle is at the repair ability that can reduce tumor cell, when increasing the chemotherapy action effect and the toxic reaction of not obvious increase medicine.Effective dose is 1-1000 milligram/patient, is ideal with 10-700 milligram/patient, with 100-500 milligram/patient for the most desirable.
The present invention can be made into different shape, and wherein the content of active ingredient is decided because of different needs.Can be made into various dosage forms, as, but be not limited to injection, muddy suspension, ointment, capsule, slow releasing agent, sustained-release implant and slow releasing injection etc.; Be different shape, as, but be not limited to granular, lamellar, sphere, bulk, needle-like, bar-shaped and film sample; Can be through various administrations, as in tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.Whether route of administration depends on multiple factor, as position, tumor place, perform the operation or transfer, gross tumor volume size, tumor classification, patient age, health, bearing status and requirement etc.For obtain active drug concentration in position, tumor place, arterial perfusion optionally, intra-bladder instillation (intracavitary), (intraspinal) administration in abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and the canalis spinalis, but also place in the internal organs, as in the enteric cavity, in the intravesical, uterine cavity, in intravaginal, gastric and the esophagus etc.In various approach, with topical, as based in selective arterial, the tumor, tumor week injection, with in the tumor, to place the form that slowly discharges serve as preferred for tumor week or tumor chamber, can plant slow-releasing pump, slow releasing capsule, slow releasing agent as selecting for use, slow releasing agent choosing group sustained-release implant and slow releasing injection.
Available arbitrary method preparation.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be in order to the manufacturing of microsphere, and its method is arbitrarily, and anti-cancer sustained-released implantation agent also can be packed in the liposome.The effective ingredient of compositions can be packaged in the whole slow-release auxiliary material equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.
Each component and the weight percentage in compositions thereof are preferred one of following in the sustained-release implant:
(A) polylactic acid of the decitabine of 1%-5% and 95%-99%;
(B) polylactic acid of the decitabine of 5%-10% and 90%-95%;
(C) polylactic acid of the decitabine of 10%-15% and 85%-90%;
(D) polylactic acid of the decitabine of 15%-25% and 75%-85%;
(E) polylactic acid of the decitabine of 25%-40% and 60%-75%;
(F) copolymer of the glycolic of the decitabine of 1%-10% and 90%-99% and hydroxyacetic acid;
(G) copolymer of the glycolic of the decitabine of 10%-20% and 80%-90% and hydroxyacetic acid;
(H) copolymer of the glycolic of the decitabine of 20%-30% and 70%-80% and hydroxyacetic acid;
(I) copolymer of the glycolic of the decitabine of 30%-40% and 60%-70% and hydroxyacetic acid;
(J) polifeprosan of the decitabine of 5%-15% and 85%-95%;
(K) polifeprosan of the decitabine of 15%-35% and 65%-85%;
(L) 5% decitabine and 95% poly-(L-lactide-co-etherophosphoric acid);
(M) 10% decitabine and 90% poly-(L-lactide-co-etherophosphoric acid);
(N) 20% decitabine and 80% poly-(L-lactide-co-etherophosphoric acid);
(O) 30% decitabine and 70% poly-(L-lactide-co-etherophosphoric acid);
(P) 5% decitabine and 95% poly-(L-lactide-co-phosphoric acid propyl ester);
(Q) 10% decitabine and 90% poly-(L-lactide-co-phosphoric acid propyl ester);
(R) 20% decitabine and 80% poly-(L-lactide-co-phosphoric acid propyl ester);
(S) 30% decitabine and 70% poly-(L-lactide-co-phosphoric acid propyl ester).
Each component and the weight percentage in compositions thereof are one of further preferred following in the sustained-release implant:
(A) mannitol of the polylactic acid of the decitabine of 1%-5% and 85%-98% and 0.5%-15%;
(B) sorbitol of the polylactic acid of the decitabine of 5%-10% and 90%-95% and 0.5%-10%;
(C) sodium chloride of the polylactic acid of the decitabine of 10%-15% and 85%-90% and 0.5%-10%;
(D) mannitol of the polylactic acid of the decitabine of 15%-25% and 75%-85% and 0.25%-5%;
(E) sorbitol of the polylactic acid 0.1%-8% of the decitabine of 25%-40% and 60%-75%;
(F) mannitol of the copolymer of the glycolic of the decitabine of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;
(G) sorbitol of the copolymer of the glycolic of the decitabine of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;
(H) sodium chloride of the copolymer of the glycolic of the decitabine of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;
(I) mannitol of the copolymer of the glycolic of the decitabine of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;
(J) mannitol of the polifeprosan of the decitabine of 5%-15% and 85%-95% and 1%-5%;
(K) mannitol of the polifeprosan of the decitabine of 15%-35% and 65%-85% and 0.25%-7.5%;
(L) 5% decitabine and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(M) 10% decitabine and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(N) 20% decitabine and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(O) 30% decitabine and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(P) 5% decitabine and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(Q) 10% decitabine and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(R) 20% decitabine and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(S) 30% decitabine and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol.
Sustained-release implant is used for the treatment of entity tumor, comprise the cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, lymphoma, tumor of head and neck and come from gallbladder, oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, eyes, former or cancer, sarcoma or the carcinosarcoma of secondary.Therefore, application of the present invention is the above-mentioned various pharmaceutical preparatioies that are used to make the above-mentioned tumor of treatment, serve as preferred wherein with injection, muddy suspension, ointment, capsule, implant, slow releasing agent and sustained-release implant, with sustained-release implant, controlled release implant or slowbreak implant for most preferably.
Also can add other medicinal ingredient in this anti-cancer sustained-released implantation agent, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.Because anti-cancer sustained-released implantation agent of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.When share with above-mentioned non-operative treatment, anti-cancer sustained-released implantation agent of the present invention can be used simultaneously with non-operative treatment, also can in implementing a few days ago, non-operative treatment use, its purpose is to strengthen as far as possible the sensitivity of tumor, thereby provide a kind of more effective new method for effecting a radical cure former of various human bodies and animal and shifting entity tumor, have very high clinical value and remarkable economical and social benefit.
When used the part, said composition can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.The outer entity tumor of cranium had the obvious treatment effect.
Anti-cancer composition of the present invention can be implemented by many schemes, and its purpose is just in order to further specify, and is not in addition any restriction of enforcement of the present invention.
Test one, decitabine are to the inhibitory action of growth of tumour cell.
Be the inhibitory action of checking decitabine to other growth of tumour cell, this test is added to decitabine (15ug/ml) in 24 hours the various tumor cells of In vitro culture (table 1), continue to cultivate after 48 hours the counting cells sum and calculates its suppression ratio to growth of tumour cell (%).
The suppression ratio of growth of tumour cell (%)=((cellular control unit is counted the test group cell number)/cellular control unit number) * 100%
Table 1
The result of test one shows that compare with matched group, decitabine all has obvious inhibitory action (P＜0.05) to the examination growth of tumor, and is wherein right.This is unexpected finds to constitute major technique feature of the present invention, for the treatment of entity tumor provides new selection.
The sustained-release implant that contains decitabine can be made into any dosage form or shape, but serves as preferred with the agent for slow releasing of implanting.
The preparation method of sustained-release implant of the present invention is as follows:
1, the slow-release auxiliary material of weighing is put into container, add the certain amount of organic solvent dissolving evenly, the not strict qualification of the amount of organic solvent, suitable fully to be dissolved as.
2, adding the anticancer active ingredient of weighing shakes up again.The usage ratio of anticancer active ingredient and slow-release auxiliary material is decided because of specific requirement.
3, remove organic solvent.Vacuum drying or cold drying all can.
4, dried solid composite is made different shape as required.
5, ray sterilizing (roentgendosis is different because of volume) is standby after the packing.Also available other method sterilization.
(4) specific embodiment
Embodiment one,
The slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 8000-15000) of (80mg) of will weighing is put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 20 milligrams of decitabines, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 20% decitabine.The drug release time of this sustained-release implant in external normal saline is 26-32 days, is 32-37 days at the subcutaneous drug release time of mice.
Embodiment two
Make sustained-release implant by embodiment one described method, but contained anticancer effective component is one of following:
(A) 1% decitabine and and 99% polylactic acid;
(B) 5% decitabine and and 95% polylactic acid;
(C) 10% decitabine and 90% polylactic acid;
(D) 15% decitabine and 85% polylactic acid;
(E) 20% decitabine and 80% polylactic acid.
Embodiment three
(molecular weight is the PLGA of 15000-25000 to the slow-release auxiliary material of (85mg) of will weighing, 50: 50) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add the 15mg decitabine, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 15% decitabine.The drug release time of this sustained-release implant in external normal saline is 26-32 days, is 26-34 days at the subcutaneous drug release time of mice.
Embodiment four
Make sustained-release implant by embodiment three described methods, contained anticancer effective component that different is is one of following:
(1) copolymer of the glycolic of the decitabine of 1%-10% and 90%-99% and hydroxyacetic acid;
(2) copolymer of the glycolic of the decitabine of 10%-20% and 80%-90% and hydroxyacetic acid;
(3) copolymer of the glycolic of the decitabine of 20%-30% and 70%-80% and hydroxyacetic acid;
(4) copolymer of the glycolic of the decitabine of 30%-40% and 60%-70% and hydroxyacetic acid;
The copolymer of (5) 5% decitabine and 95% glycolic and hydroxyacetic acid;
The copolymer of (6) 10% decitabine and 90% glycolic and hydroxyacetic acid;
The copolymer of (7) 20% decitabine and 80% glycolic and hydroxyacetic acid;
The copolymer of (8) 30% decitabine and 70% glycolic and hydroxyacetic acid.
Embodiment five
(molecular weight is the PLGA of 25000-30000 to the 85mg slow-release auxiliary material of will weighing, 75: 25) put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion), add 10mg decitabine and 5mg mannitol, shake up the dry organic solvent of removing of final vacuum again with abundant dissolving.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 10% decitabine.The drug release time of this sustained-release implant in external normal saline is 25-32 days, is 25-29 days at the subcutaneous drug release time of mice.
Embodiment six
Make sustained-release implant by embodiment five described methods, contained anticancer effective component that different is is one of following:
(1) mannitol of the copolymer of the glycolic of the decitabine of 1%-10% and 90%-99% and hydroxyacetic acid and 0.5%-15%;
(2) sorbitol of the copolymer of the glycolic of the decitabine of 10%-20% and 80%-90% and hydroxyacetic acid and 0.5%-10%;
(3) sodium chloride of the copolymer of the glycolic of the decitabine of 20%-30% and 70%-80% and hydroxyacetic acid and 0.5%-10%;
(4) mannitol of the copolymer of the glycolic of the decitabine of 30%-40% and 60%-70% and hydroxyacetic acid and 0.25%-5%;
The copolymer of (5) 5% decitabine and 92% glycolic and hydroxyacetic acid and 2% sodium chloride;
The copolymer of (6) 10% decitabine and 85% glycolic and hydroxyacetic acid and 5% mannitol;
The copolymer of (7) 20% decitabine and 75% glycolic and hydroxyacetic acid and 5% mannitol;
The copolymer of (8) 30% decitabine and 75% glycolic and hydroxyacetic acid and 5% mannitol.
Embodiment seven
85 mg polifeprosans (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 50: 50) are put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 15mg decitabine, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 15% decitabine sustained-release implant.The drug release time of this sustained-release implant in external normal saline is 11-15 days, is 12-18 days at the subcutaneous drug release time of mice
Embodiment eight
Make sustained-release implant by embodiment seven described methods, that contained anticancer effective component is is one of following but different is:
(1) polifeprosan of the decitabine of 1%-15% and 85%-95%;
(2) polifeprosan of the decitabine of 15%-35% and 65%-85%;
(3) 5% decitabine and 95% polifeprosan;
(4) 10% decitabine and 90% polifeprosan;
(5) 15% decitabine and the polifeprosan of 85%-95%;
(6) 20% decitabine and 80% polifeprosan.
Embodiment nine
80mg polifeprosan (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) is 30: 70) and 5mg sodium chloride are put into container, add 100 milliliters of dichloromethane dissolving mixings after, add the 15mg decitabine, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain percentage by weight 15% decitabine sustained-release implant.The drug release time of this sustained-release implant in external normal saline is 12-20 days, is 15-19 days at the subcutaneous drug release time of mice.
Embodiment ten
Make sustained-release implant by embodiment ten described methods, that contained anticancer effective component is is one of following but different is:
(1) mannitol of the polifeprosan of the decitabine of 5%-15% and 85%-95% and 1%-5%; Or
(2) mannitol of the polifeprosan of the decitabine of 15%-35% and 65%-85% and 0.25%-7.5%.
Embodiment 11
85mg slow-release auxiliary material (molecular weight is the polylactic acid (PLA) of 15000-30000) and 10mg mannitol are put into container, after adding certain amount of organic solvent dissolving mixing (being as the criterion) with abundant dissolving, add 5 milligrams of decitabines, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing obtains sustained-release implant and contains 5% decitabine.The drug release time of this sustained-release implant in external normal saline is 24-29 days, is 26-32 days at the subcutaneous drug release time of mice.
Embodiment 12
Make sustained-release implant by embodiment 11 described methods, used slow-release auxiliary material is selected from one of following or its combination:
(A) 1% decitabine and and 95% polylactic acid and 4% mannitol;
(B) 5% decitabine and and 93% polylactic acid and 2% mannitol;
(C) 10% decitabine and 85% polylactic acid and 5% mannitol;
(D) 15% decitabine and 82% polylactic acid and 3% sodium chloride;
(E) 20% decitabine and 78% polylactic acid and 2% sodium chloride.
Embodiment 13
Make sustained-release implant by embodiment 1 to 11 described method, used slow-release auxiliary material is selected from one of following or its combination:
A) molecular weight is the polylactic acid (PLA) of 10000-20000,20000-35000 or 30000-50000;
B) molecular weight is the polylactic acid of 15000-35000,35000-45000 or 45000-80000 and the copolymer of hydroxyacetic acid (PLGA);
C) polifeprosan is (to carboxy phenyl propane (p-CPP): decanedioic acid (SA) copolymer), be 20: 80,30: 70,40: 60,50: 50 or 60: 40 to the percentage by weight of carboxy phenyl propane (p-CPP) and decanedioic acid (SA).
On the basis of above-mentioned slow release, the present invention finds that further body is implanted into decitabine other entity tumors such as hepatocarcinoma, pulmonary carcinoma, breast carcinoma, cancer of pancreas, colon cancer, rectal cancer, ovarian cancer, skin carcinoma, lymphoma and carcinoma of prostate are also had good therapeutical effect.Topical remedy's slow release in the stable lastingly and drug level, has obviously reduced systemic drug concentration in having guaranteed local application's scope, alleviated toxic and side effects.Following in vivo test is used for explanation but not limitation of the present invention.
Embodiment 14
With 70,80,90 and 95mg molecular weight peak value be that the p (LAEG-EOP) of 10000-25000 puts into first, second, third, four containers of fourth respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in four containers, add 30mg, 20mg, 10mg and 5mg decitabine respectively, shake up the sustained-release implant that the preparation of after drying method contains 30%, 20%, 10% and 5% decitabine again.The drug release time of this slow releasing agent in external normal saline is 48-52 days, is about 46-54 days at the subcutaneous drug release time of mice.
Embodiment 15
The method step that is processed into sustained-release implant is identical with embodiment 14, but the molecular weight peak value of different is p (LAEG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:
(1) 1%-5% decitabine;
(2) 5%-10% decitabine;
(3) 10%-20% decitabine;
(4) 20%-40% decitabine;
The sodium chloride of (5) 5% decitabine and 92% p (LAEG-EOP) and 2%;
The mannitol of (6) 10% decitabine and 85% p (LAEG-EOP) and 5%;
The mannitol of (7) 20% decitabine and 75% p (LAEG-EOP) and 5%;
The mannitol of (8) 30% decitabine and 75% p (LAEG-EOP) and 5%.
Embodiment 16
With 70,80,90 and 95mg molecular weight peak value be that the p (DAPG-EOP) of 10000-25000 puts into first, second, third, four containers of fourth respectively, add 100 milliliters of dichloromethane then in each, behind the dissolving mixing, in four containers, add 30mg, 20mg, 10mg and 5mg decitabine respectively, shake up the sustained-release implant that the preparation of after drying method contains 30%, 20%, 10% and 5% decitabine again.The drug release time of this slow releasing agent in external normal saline is 46-52 days, is about 48-56 days at the subcutaneous drug release time of mice.
Embodiment 17
The method step that is processed into sustained-release implant is identical with embodiment 16, but the molecular weight peak value of different is p (DAPG-EOP) is 25000-45000, and contained anticancer effective component and percentage by weight thereof are:
(1) 1%-5% decitabine;
(2) 5%-10% decitabine;
(3) 10%-20% decitabine;
(4) 20%-40% decitabine;
The sodium chloride of (5) 5% decitabine and 92% p (DAPG-EOP) and 2%;
The mannitol of (6) 10% decitabine and 85% p (DAPG-EOP) and 5%;
The mannitol of (7) 20% decitabine and 75% p (DAPG-EOP) and 5%;
The mannitol of (8) 30% decitabine and 75% p (DAPG-EOP) and 5%.
Embodiment 18, tumor are implanted into the inhibitory action of decitabine to entity tumor
Method and step: tumor cell inoculation is subcutaneous in the right side of mice axillary fossa, when tumor growth is divided into 7 groups, 5 every group at random with animal during to the 0.8cm left and right sides.Be normal saline group, decitabine lumbar injection group (hereinafter to be referred as decitabine abdominal cavity group), decitabine local injection group (being called for short the decitabine partial groups), high molecular polymer group (being called for short high poly-group), decitabine sustained-release implant group with the made sustained-release implant (being called for short implant 5%, implant 10%, implant 20%) of embodiment four.With 70% alcohol disinfecting tumor surface skin, selection is apart from tumor lower edge 1cm place, cut off the long otch of 1mm, with puncture needle with in the decitabine implant implantation tumour tissue, not pastille high molecular polymer, decitabine implant 5%, decitabine implant 10%, decitabine implant 20%.Sew up the incision and prevent that implant from spilling.Put to death animal in 15 days with vernier caliper measurement tumor size after the implant embedding in per 3 days, the back of weighing is complete peels off tumor and claims tumor heavy.Calculate tumor control rate % with following formula.
Tumor control rate=(the average tumor of the average tumor weight/normal saline of 1-administration group group is heavy) * 100%
Embodiment 19, tumor are implanted into the tumor-inhibiting action of decitabine spit of fland sustained-release implant to mice lung cancer
Check the tumor-inhibiting action of decitabine sustained-release implant according to embodiment 18 described methods and step to mice lung cancer.Used implant adjuvant is PLGA (molecular weight is 15000-25000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50), is derived from embodiment four.The decitabine implant of this experimental result proof various dose can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Decitabine implant tumor control rate is respectively 38%, 62%, 72%, compares with decitabine local injection group, and the P value is all less than 0.001.Repeated experiments: tumor control rate is respectively 40%, 50%, 74%, compares with the local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Decitabine lumbar injection group and decitabine local injection group and normal saline group comparison of tumor suppression ratio are 12% and 16%, and repeated experiments: tumor control rate is 16% and 15%.The tumour inhibiting rate of decitabine implant obviously surpasses decitabine lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 20 tumors are implanted into the tumor-inhibiting action of decitabine sustained-release implant to mouse breast cancer
Check the tumor-inhibiting action of decitabine sustained-release implant to mouse breast cancer according to embodiment 18 described methods and step, used implant is from embodiment two.Experimental result shows that the tumor control rate of 1%, 10% and 25% decitabine implant is respectively 40%, 52%, 68%, compares with decitabine local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 42%, 62%, 75%, compares with decitabine local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Decitabine lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 12% and 14%, and repeated experiments: tumor control rate is 10% and 12%.The tumour inhibiting rate of decitabine implant obviously surpasses decitabine lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 21, tumor are implanted into the tumor-inhibiting action of decitabine sustained-release implant to the mouse ovarian cancer
Check the tumor-inhibiting action of decitabine sustained-release implant according to embodiment 18 described methods and step to the mouse ovarian cancer, used implant is 5%, 10% and 20% polifeprosan (percentage by weight to carboxy phenyl propane (p-CPP) and decanedioic acid (SA) is 50: 50), from embodiment eight.The decitabine implant of experimental result proof various dose is implanted in the mouse ovarian cancer and can obviously be suppressed tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Decitabine implant tumor control rate is respectively 42%, 54%, 76%, compares with decitabine local injection group, and low dose group P value equals 0.001, and middle and high dosage group P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 42%, 58%, 78%, compares with decitabine local injection group, and low dose group P value is less than 0.05, and middle and high dosage group P value is all less than 0.001.Difference has the height statistical significance.Decitabine lumbar injection group and decitabine local injection group and normal saline group comparison of tumor suppression ratio are 12% and 20%, and repeated experiments: tumor control rate is 12% and 16%.The tumour inhibiting rate of decitabine implant obviously surpasses decitabine lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 22 tumors are implanted into the tumor-inhibiting action of decitabine sustained-release implant to the mice esophageal carcinoma
Check the tumor-inhibiting action of decitabine sustained-release implant to the mice esophageal carcinoma according to embodiment 18 described methods and step, used implant is selected from embodiment six.The decitabine implant of experimental result proof various dose is implanted in nude mice model human esophagus cancer (9706) entity tumor, all can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Decitabine implant tumor control rate is respectively 40%, 56%, 76%, compares with decitabine local injection group, and the P value is all less than 0.001.Repeated experiments finds that tumor control rate is respectively 40%, 62%, 78%, compares with decitabine local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Decitabine lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 10% and 14%, and repeated experiments shows that tumor control rate is 12% and 12%.The tumour inhibiting rate of decitabine implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 23, tumor are implanted into the tumor-inhibiting action of decitabine sustained-release implant to mouse pancreas cancer
Check the tumor-inhibiting action of decitabine sustained-release implant to mouse pancreas cancer according to embodiment 18 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50).The content of decitabine in sustained-release implant be 2.5%, 7.5% and the decitabine implant of 12.5%. experimental result proof various dose implant in nude mice model human pancreas cancer (JF305) entity tumor, can obviously suppress tumor growth, tumor control rate and drug dose are obvious dose-effect relationship.Decitabine implant tumor control rate is respectively 46%, 56%, 80%, compares with decitabine local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 48%, 58%, 76%, compares with decitabine local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Decitabine lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 11% and 14%.Repeated experiments finds that tumor control rate is 10% and 16%.The tumour inhibiting rate of decitabine implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 24, tumor are implanted into the tumor-inhibiting action of decitabine sustained-release implant to the mice rectal cancer
Check the tumor-inhibiting action of decitabine sustained-release implant to the mice rectal cancer according to embodiment 18 described methods and step, used implant adjuvant is PLGA (molecular weight is 20000-35000, and the blending ratio of glycolic and hydroxyacetic acid is 50: 50).The content of decitabine in sustained-release implant is the decitabine implant of 7.5%, 15% and 25%. experimental results proof various dose, can obviously suppress tumor growth, and tumor control rate and drug dose are obvious dose-effect relationship.Decitabine implant tumor control rate is respectively 40%, 72%, 86%, compares with decitabine local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 50%, 60%, 70%, compares with decitabine local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Decitabine lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 20% and 18%.Repeated experiments finds that tumor control rate is 12% and 10%.The tumour inhibiting rate of decitabine implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 25, tumor are implanted into the tumor-inhibiting action of decitabine sustained-release implant to the mice carcinoma of prostate
Check the tumor-inhibiting action of decitabine sustained-release implant to the mice carcinoma of prostate according to embodiment 18 described methods and step, used implant adjuvant is p (LAEG-EOP) (molecular weight is 10000-25000).The content of decitabine in sustained-release implant is 5%, 10% and 20% (from embodiment 14). the decitabine implant of experimental result proof various dose is implanted in the nude mice model human prostata cancer entity tumor, can obviously suppress tumor growth, tumor control rate and drug dose are obvious dose-effect relationship.Decitabine implant tumor control rate is respectively 48%, 52%, 78%, compares with decitabine local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 52%, 68%, 82%, compares with decitabine local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Decitabine lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 21% and 14%.Repeated experiments finds that tumor control rate is 12% and 14%.The tumour inhibiting rate of decitabine implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
Embodiment 26, tumor are implanted into the tumor-inhibiting action of decitabine sustained-release implant to rat liver cancer
Check the tumor-inhibiting action of decitabine sustained-release implant to rat liver cancer according to embodiment 18 described methods and step, used implant adjuvant is p (DAPG-EOP) (molecular weight is 10000-25000).The content of decitabine in sustained-release implant is 5%, 10% and 20% (from embodiment 16). the content of decitabine in sustained-release implant is the decitabine implant of 7.5%, 15% and 25%. experimental results proof various dose, can obviously suppress tumor growth, tumor control rate and drug dose are obvious dose-effect relationship.Decitabine implant tumor control rate is respectively 50%, 64%, 78%, compares with decitabine local injection group, and the P value is all less than 0.001.Repeated experiments shows that tumor control rate is respectively 52%, 66%, 86%, compares with decitabine local injection group, and the P value is all less than 0.001.Difference has the height statistical significance.Decitabine lumbar injection group and local injection group and normal saline group comparison of tumor suppression ratio are 16% and 8%.Repeated experiments finds that tumor control rate is 8% and 10%.The tumour inhibiting rate of decitabine implant obviously surpasses lumbar injection group and local injection group, twice experimental result good reproducibility.
In addition, tumor is implanted into the decitabine sustained-release implant other entity tumors such as the cerebral tumor, cervical cancer, gastric cancer, bladder cancer, carcinoma of testis, carcinoma of endometrium, lymphoma, renal carcinoma is also had good therapeutical effect, and its effect obviously surpasses decitabine lumbar injection group and local injection group.This is unexpected finds to constitute another major technique feature of the present invention, for the treatment of entity tumor provides another new selection.
Claims (10)
1. a decitabine sustained-release preparation for the treatment of entity tumor is characterized in that this slow releasing agent contains the decitabine of effective anticancer, slow-release auxiliary material and a certain amount of slow release regulator, and wherein the weight ratio of each constituent is:
(1) decitabine 0.1%-50%
(2) slow-release auxiliary material 50%-99%
(3) slow release regulator 0-15%
Below all be weight percentage.
2. the slow releasing agent according to claim 1 is characterized in that slow-release auxiliary material is selected from a kind of or its combination in the copolymer of polylactic acid, polylactic acid and hydroxyacetic acid, polifeprosan, poly-(L-lactide-co-etherophosphoric acid), poly-(the L-lactide-co-phosphoric acid propyl ester).
3. the slow releasing agent according to claim 1 is characterized in that the slow release regulator is selected from a kind of or its combination in xylitol, oligosaccharide, chitin, potassium salt, sodium salt, mannitol, sorbitol, the chrondroitin.
4. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(A) 1% decitabine and and 99% polylactic acid;
(B) 5% decitabine and and 95% polylactic acid;
(C) 10% decitabine and 90% polylactic acid;
(D) 15% decitabine and 85% polylactic acid;
(E) 20% decitabine and 80% polylactic acid;
(F) 5% decitabine and 95% glycolic and the copolymer of hydroxyacetic acid;
(G) 10% decitabine and 90% glycolic and the copolymer of hydroxyacetic acid;
(H) 20% decitabine and 80% glycolic and the copolymer of hydroxyacetic acid;
(I) 30% decitabine and 70% glycolic and the copolymer of hydroxyacetic acid;
(J) 5% decitabine and 95% polifeprosan;
(K) 15% decitabine and 85% polifeprosan;
(L) 5% decitabine and 95% poly-(L-lactide-co-etherophosphoric acid);
(M) 10% decitabine and 90% poly-(L-lactide-co-etherophosphoric acid);
(N) 20% decitabine and 80% poly-(L-lactide-co-etherophosphoric acid);
(O) 30% decitabine and 70% poly-(L-lactide-co-etherophosphoric acid);
(P) 5% decitabine and 95% poly-(L-lactide-co-phosphoric acid propyl ester);
(Q) 10% decitabine and 90% poly-(L-lactide-co-phosphoric acid propyl ester);
(R) 20% decitabine and 80% poly-(L-lactide-co-phosphoric acid propyl ester);
(S) 30% decitabine and 70% poly-(L-lactide-co-phosphoric acid propyl ester).
5. the sustained-release implant according to claim 1 is characterized in that in the anticancer effective component of this sustained-release implant that each component and the weight percentage in implant thereof are one of following:
(A) 1% decitabine and and 95% polylactic acid and 4% mannitol;
(B) 5% decitabine and and 93% polylactic acid and 2% mannitol;
(C) 10% decitabine and 85% polylactic acid and 5% mannitol;
(D) 15% decitabine and 82% polylactic acid and 3% sodium chloride;
(E) 20% decitabine and 78% polylactic acid and 2% sodium chloride;
(F) 5% decitabine and 92% glycolic and the copolymer of hydroxyacetic acid and 2% sodium chloride;
(G) 10% decitabine and 85% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;
(H) 20% decitabine and 75% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;
(I) 30% decitabine and 75% glycolic and the copolymer of hydroxyacetic acid and 5% mannitol;
(J) 5% decitabine and 92.5% polifeprosan and 2.5% mannitol;
(K) 15% decitabine and 75% polifeprosan and 10% mannitol;
(L) 5% decitabine and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(M) 10% decitabine and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(N) 20% decitabine and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(O) 30% decitabine and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(P) 5% decitabine and 92% poly-(L-lactide-co-etherophosphoric acid) and 2% sodium chloride;
(Q) 10% decitabine and 85% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(R) 20% decitabine and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol;
(S) 30% decitabine and 75% poly-(L-lactide-co-etherophosphoric acid) and 5% mannitol.
6. according to the described anticancer sustained-release agent of claim 1-5, the molecular weight peak value that it is characterized in that polylactic acid is 5000-15000,10000-20000,20000-35000 or 30000-50000.
7. according to the described anticancer sustained-release agent of claim 1-5, the molecular weight peak value that it is characterized in that the copolymer of glycolic and hydroxyacetic acid is 5000-15000,15000-35000,35000-45000 or 45000-80000; The percentage by weight of glycolic and hydroxyacetic acid is 80: 20,75: 25, and 70: 30,60: 40,50: 50 or 40: 60.
8. according to the described anticancer sustained-release agent of claim 1-5, it is characterized in that the percentage by weight to carboxy phenyl propane and decanedioic acid is 20: 80 in the polifeprosan (to carboxy phenyl propane-decanedioic acid copolymer), 30: 70,40: 60,50: 50 or 60: 40.
9. the described slow releasing agent of claim 1-5 is characterized in that this slow releasing agent is in the tumor or the slow releasing injection and the solid sustained-release implant of all injections of tumor or placement.
10. the slow releasing agent according to claim 1 is characterized in that described slow releasing agent is used to prepare the treatment cerebral tumor, hepatocarcinoma, pulmonary carcinoma, the esophageal carcinoma, gastric cancer, breast carcinoma, cancer of pancreas, thyroid carcinoma, nasopharyngeal carcinoma, ovarian cancer, carcinoma of endometrium, cervical cancer, renal carcinoma, carcinoma of prostate, bladder cancer, colon cancer, rectal cancer, carcinoma of testis, skin carcinoma, lymphoma, tumor of head and neck and originates from the pharmaceutical preparation of cancer, sarcoma or the carcinosarcoma of gallbladder, oral cavity, peripheral nervous system, mucosa, body of gland, blood vessel, osseous tissue, lymph node, eyes former or secondary.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007102030552A CN101185629A (en) | 2007-12-14 | 2007-12-14 | Decitabine sustained-release preparation for treating solid tumor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007102030552A CN101185629A (en) | 2007-12-14 | 2007-12-14 | Decitabine sustained-release preparation for treating solid tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101185629A true CN101185629A (en) | 2008-05-28 |
Family
ID=39478389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007102030552A Pending CN101185629A (en) | 2007-12-14 | 2007-12-14 | Decitabine sustained-release preparation for treating solid tumor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101185629A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088969B (en) * | 2008-06-09 | 2013-06-12 | 西克拉塞尔有限公司 | Combination of spacitabine (CNDAC) and DNA methyltransferase inhibitors such as decitabine and procaine |
| US10226478B2 (en) | 2011-04-14 | 2019-03-12 | Cyclacel Limited | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
| CN115778962A (en) * | 2022-11-28 | 2023-03-14 | 中国医学科学院肿瘤医院 | Drugs for the treatment of male patients with esophageal cancer and their related applications |
-
2007
- 2007-12-14 CN CNA2007102030552A patent/CN101185629A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102088969B (en) * | 2008-06-09 | 2013-06-12 | 西克拉塞尔有限公司 | Combination of spacitabine (CNDAC) and DNA methyltransferase inhibitors such as decitabine and procaine |
| US8530445B2 (en) | 2008-06-09 | 2013-09-10 | Cyclacel Limited | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine |
| US8975239B2 (en) | 2008-06-09 | 2015-03-10 | Cyclacel Limited | Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine |
| US10226478B2 (en) | 2011-04-14 | 2019-03-12 | Cyclacel Limited | Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia |
| CN115778962A (en) * | 2022-11-28 | 2023-03-14 | 中国医学科学院肿瘤医院 | Drugs for the treatment of male patients with esophageal cancer and their related applications |
| CN115778962B (en) * | 2022-11-28 | 2024-09-17 | 中国医学科学院肿瘤医院 | Medicine for treating male esophageal cancer patient and related application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101185633A (en) | Neratinib sustained-release implant for treating solid tumor | |
| CN101185627B (en) | Nilotinib sustained-release implant for treating solid tumor | |
| CN101219102A (en) | Lapatinib sustained-release implantation agent for treating solid tumors | |
| CN101181230A (en) | Estramustine sustained-release implantation agent for curing entity tumour | |
| CN100563644C (en) | A kind of carmustine sustained-release implantation agent for the treatment of entity tumor | |
| CN101185629A (en) | Decitabine sustained-release preparation for treating solid tumor | |
| CN101176713B (en) | Carmustine sustained-release implantation agent for curing entity tumour | |
| CN101204365A (en) | Implant agent treating for solid tumor | |
| CN101219101A (en) | Fludarabine sustained-release implantation agent for treating solid tumors | |
| CN101181232B (en) | Marseilledinun sustained-release implantation agent for curing entity tumour | |
| CN101224185A (en) | Bosutinib sustained release implant for treating solid tumors | |
| CN101204367A (en) | Axitinib sustained-release implplant treating for solid tumor | |
| CN100563645C (en) | A kind of Beisalutin sustained-release implantation agent for the treatment of entity tumor | |
| CN101176710A (en) | Mitoxantrone sustained-release implantation agent for curing entity tumour | |
| CN101204369A (en) | Sorafenib sustained-release implant treating for solid tumor | |
| CN101219105A (en) | Emtricitabine sustained-release implantation agent for treating solid tumors | |
| CN101204366A (en) | Melphalan sustained-release implant treating for solid tumor | |
| CN101181235B (en) | Tantudinun sustained-release implantation agent for curing entity tumour | |
| CN101181229A (en) | Busulfan sustained-release implantation agent for curing entity tumour | |
| CN101176715A (en) | Gefitinib sustained-release implantation agent for curing entity tumour | |
| CN101181234B (en) | Literdinun sustained-release implantation agent for curing entity tumour | |
| CN101185632A (en) | Lonafarnib sustained-release implant for treating solid tumor | |
| CN101181231B (en) | Sustained-release implantation agent of urotrotiken | |
| CN100531712C (en) | A dasatinib slow-release implant for treating solid tumors | |
| CN101185625B (en) | Rubitecan sustained-release implant for treating solid tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080528 |